CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population

BMC Medical Genetics

Volumn 12, Issue , 2011, Pages

  Santos, Paulo C J L ^a   Soares, Renata A G ^a   Santos, Diogo B G ^a   Nascimento, Raimundo M ^b   Coelho, George L L M ^b   Nicolau, José C ^a   Mill, José G ^c   Krieger, José E ^a   Pereira, Alexandre C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^c FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; MULTIDRUG RESISTANCE PROTEIN 1; ABCB1 PROTEIN, HUMAN; ANTITHROMBOCYTIC AGENT; CYP2C19 PROTEIN, HUMAN; DRUG DERIVATIVE; GLYCOPROTEIN P; TICLOPIDINE; UNSPECIFIC MONOOXYGENASE;

ADULT; AFRICA; AMERICAN INDIAN; ARTICLE; BRAZIL; CAUCASIAN; CHROMOSOME HIGH RESOLUTION BANDING ANALYSIS; COST EFFECTIVENESS ANALYSIS; DNA POLYMORPHISM; ETHNIC DIFFERENCE; ETHNICITY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENOTYPE; HUMAN; INDIVIDUALIZATION; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; POPULATION; PREDICTION; PREVALENCE; ETHNIC GROUP; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MIDDLE AGED; STATISTICS;

ADULT; ARYL HYDROCARBON HYDROXYLASES; BRAZIL; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; HUMANS; INDIANS, SOUTH AMERICAN; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; TICLOPIDINE;

EID: 78651498123     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-12-13     Document Type: Article

References (34)

1. Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, Ikeda T, Kurihara A. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 38(1):92-99. 10.1124/dmd.109.029132, 19812348.
2. Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov 9(2):154-169. 10.1038/nrd2957, 20118963.
3. Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, Stratz C, Schmiebusch P, Bestehorn HP, Buttner HJ, et al. Cytochrome P450 2C19 681G > A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008, 51(20):1925-1934. 10.1016/j.jacc.2007.12.056, 18482659.
4. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009, 373(9660):309-317. 10.1016/S0140-6736(08)61845-0, 19108880.
5. Geisler T, Schaeffeler E, Dippon J, Winter S, Buse V, Bischofs C, Zuern C, Moerike K, Gawaz M, Schwab M. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics 2008, 9(9):1251-1259. 10.2217/14622416.9.9.1251, 18781853.
6. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009, 360(4):354-362. 10.1056/NEJMoa0809171, 19106084.
7. Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, Morath T, Schomig A, von Beckerath N, Kastrati A. Cytochrome 2C1917 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 121(4):512-518. 10.1161/CIRCULATIONAHA.109.885194, 20083681.
8. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, Steg PG, Ferrieres J, Danchin N, Becquemont L. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009, 360(4):363-375. 10.1056/NEJMoa0808227, 19106083.
9. Steinhubl SR. Genotyping, clopidogrel metabolism, and the search for the therapeutic window of thienopyridines. Circulation 121(4):481-483. 10.1161/CIR.0b013e3181d1e0e1, 20083686.
10. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006, 79(1):103-113. 10.1016/j.clpt.2005.10.002, 16413245.
11. Taubert D, von Beckerath N, Grimberg G, Lazar A, Jung N, Goeser T, Kastrati A, Schomig A, Schomig E. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 2006, 80(5):486-501. 10.1016/j.clpt.2006.07.007, 17112805.
12. Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, Thornton N, Folayan GO, Githang'a J, Indalo A, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001, 11(3):217-221. 10.1097/00008571-200104000-00005, 11337937.
13. Ozawa S, Soyama A, Saeki M, Fukushima-Uesaka H, Itoda M, Koyano S, Sai K, Ohno Y, Saito Y, Sawada J. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet 2004, 19(2):83-95. 10.2133/dmpk.19.83, 15499174.
14. Santos PC, Cancado RD, Terada CT, Rostelato S, Gonzales I, Hirata RD, Hirata MH, Chiattone CS, Guerra-Shinohara EM. HFE gene mutations and iron status of Brazilian blood donors. Braz J Med Biol Res 43(1):107-114.
15. Makdisse M, Pereira Ada C, Brasil Dde P, Borges JL, Machado-Coelho GL, Krieger JE, Nascimento Neto RM, Chagas AC. Prevalence and risk factors associated with peripheral arterial disease in the Hearts of Brazil Project. Arq Bras Cardiol 2008, 91(6):370-382. 10.1590/S0066-782X2008001800008, 19142364.
16. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16(3):1215. 10.1093/nar/16.3.1215, 334765, 3344216.
17. Santos DG, Resende MF, Mill JG, Mansur AJ, Krieger JE, Pereira AC. Nuclear Factor(NF) kappaB polymorphism is associated with heart function in patients with heart failure. BMC Med Genet 11(1):89. 10.1186/1471-2350-11-89, 2897791, 20534156.
18. Alvim RO, Freitas SR, Ferreira NE, Santos PC, Cunha RS, Mill JG, Krieger JE, Pereira AC. APOE polymorphism is associated with lipid profile, but not with arterial stiffness in the general population. Lipids Health Dis 9:128. 10.1186/1476-511X-9-128, 2992057, 21059196.
19. Gladding P, Webster M, Zeng I, Farrell H, Stewart J, Ruygrok P, Ormiston J, El-Jack S, Armstrong G, Kay P, et al. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv 2008, 1(6):620-627. 10.1016/j.jcin.2008.09.008, 19463375.
20. Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT, Chen CH, Motsinger-Reif A, Sagreiya H, Liu N, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 115(18):3827-3834. 10.1182/blood-2009-12-255992, 20203262.
21. Ross KA, Bigham AW, Edwards M, Gozdzik A, Suarez-Kurtz G, Parra EJ. Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. J Hum Genet 55(9):582-589. 10.1038/jhg.2010.73, 20555338.
22. Roberts RL, Joyce PR, Mulder RT, Begg EJ, Kennedy MA. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J 2002, 2(3):191-196. 10.1038/sj.tpj.6500099, 12082591.
23. Li Y, Wang Y, Sun J, Yang L. Distribution of the functional MDR1 C3435T polymorphism in the Han population of China. Swiss Med Wkly 2006, 136(23-24):377-382.
24. Bernal ML, Sinues B, Fanlo A, Mayayo E. Frequency distribution of C3435T mutation in exon 26 of the MDR1 gene in a Spanish population. Ther Drug Monit 2003, 25(1):107-111. 10.1097/00007691-200302000-00016, 12548153.
25. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000, 97(7):3473-3478. 10.1073/pnas.050585397, 16264, 10716719.
26. Mrozikiewicz PM, Seremak-Mrozikiewicz A, Semczuk A, Landt O, Breborowicz GH, Drews K. The significance of C3435T point mutation of the MDR1 gene in endometrial cancer. Int J Gynecol Cancer 2007, 17(3):728-731. 10.1111/j.1525-1438.2007.00821.x, 17300681.
27. Scordo MG, Caputi AP, D'Arrigo C, Fava G, Spina E. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 2004, 50(2):195-200. 10.1016/j.phrs.2004.01.004, 15177309.
28. Aynacioglu AS, Sachse C, Bozkurt A, Kortunay S, Nacak M, Schroder T, Kayaalp SO, Roots I, Brockmoller J. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther 1999, 66(2):185-192.
29. Chang M, Dahl ML, Tybring G, Gotharson E, Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995, 5(6):358-363. 10.1097/00008571-199512000-00004, 8747407.
30. Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, Evans DA. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997, 7(1):59-64. 10.1097/00008571-199702000-00008, 9110363.
31. Sugimoto K, Uno T, Yamazaki H, Tateishi T. Limited frequency of the CYP2C1917 allele and its minor role in a Japanese population. Br J Clin Pharmacol 2008, 65(3):437-439. 10.1111/j.1365-2125.2007.03057.x, 2291245, 18241287.
32. Ramsjo M, Aklillu E, Bohman L, Ingelman-Sundberg M, Roh HK, Bertilsson L. CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking. Eur J Clin Pharmacol 2010, 66(9):871-877. 10.1007/s00228-010-0835-0, 20499227.
33. Ragia G, Arvanitidis KI, Tavridou A, Manolopoulos VG. Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C1917 discovery: the case of Greece. Pharmacogenomics 2009, 10(1):43-49. 10.2217/14622416.10.1.43, 19102714.
34. Sibbing D, Stegherr J, Latz W, Koch W, Mehilli J, Dorrler K, Morath T, Schomig A, Kastrati A, von Beckerath N. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 2009, 30(8):916-922. 10.1093/eurheartj/ehp041, 19193675.